- Home
- MAX vs CRGX Comparison
MAX vs CRGX Comparison
Compare MAX & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- CRGX
- Stock Information
- Founded
- MAX 2014
- CRGX 2021
- Country
- MAX United States
- CRGX United States
- Employees
- MAX N/A
- CRGX N/A
- Industry
- MAX Industrial Machinery/Components
- CRGX
- Sector
- MAX Industrials
- CRGX
- Exchange
- MAX Nasdaq
- CRGX Nasdaq
- Market Cap
- MAX 582.4M
- CRGX 190.0M
- IPO Year
- MAX 2020
- CRGX 2023
- Fundamental
- Price
- MAX $10.44
- CRGX $4.61
- Analyst Decision
- MAX Strong Buy
- CRGX Hold
- Analyst Count
- MAX 6
- CRGX 7
- Target Price
- MAX $17.92
- CRGX $5.33
- AVG Volume (30 Days)
- MAX 394.0K
- CRGX 2.0M
- Earning Date
- MAX 07-30-2025
- CRGX 08-11-2025
- Dividend Yield
- MAX N/A
- CRGX N/A
- EPS Growth
- MAX N/A
- CRGX N/A
- EPS
- MAX 0.28
- CRGX N/A
- Revenue
- MAX $1,002,364,000.00
- CRGX N/A
- Revenue This Year
- MAX $24.09
- CRGX $57.81
- Revenue Next Year
- MAX $11.18
- CRGX N/A
- P/E Ratio
- MAX $37.11
- CRGX N/A
- Revenue Growth
- MAX 148.62
- CRGX N/A
- 52 Week Low
- MAX $7.33
- CRGX $3.00
- 52 Week High
- MAX $20.91
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- MAX 49.08
- CRGX 61.57
- Support Level
- MAX $10.28
- CRGX $4.32
- Resistance Level
- MAX $11.14
- CRGX $4.63
- Average True Range (ATR)
- MAX 0.34
- CRGX 0.15
- MACD
- MAX -0.06
- CRGX 0.04
- Stochastic Oscillator
- MAX 39.21
- CRGX 76.44
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.